Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates lipopolysaccharide-induced cellular injury in lung alveolar epithelial cells

Basit Öğe Kaydı
dc.authoridVICIL, SINAN/0000-0002-0444-4771
dc.authorwosidVicil, Sinan/A-6412-2016
dc.contributor.authorVicil, Sinan
dc.contributor.authorErdogan, Suat
dc.date.accessioned2024-06-12T11:07:55Z
dc.date.available2024-06-12T11:07:55Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground/aim: Human alveolar epithelial cells play a critical role in the pathogenesis of lung diseases. The objective of this study is to determine the contribution of beraprost sodium, a prostaglandin I-2 (PGI(2)) analogue, to inflammatory and oxidative events in response to lipopolysaccharide (LPS) in airway epithelial cells. Materials and methods: Human pulmonary alveolar epithelial cells (A549) were pretreated with 10 mu M beraprost sodium 30 min before stimulation with 1 mu g/mL LPS for 24 h. The cellular viability assessments were evaluated by quantitative MTT test. Catalase activity and glutathione and lipid peroxidation levels were determined using spectrophotometric techniques. mRNA expression analyses were performed by real-time qRT-PCR. Results: The endotoxin induced a dose-dependent increase in proliferation of the cells, which was suppressed by the beraprost sodium treatment. LPS increased the expressions of TNF-alpha and IL-1 beta genes by 8- and 2.5-fold, respectively. It also induced lipid peroxidation and depleted cellular antioxidant capacity. Pretreatments of the cells with beraprost sodium significantly reversed the inflammation and suppressed oxidative stress. Conclusion: These findings suggest that beraprost sodium will provide a pivotal molecular basis for the design of new therapeutic strategies to cure endotoxin-induced lung injury, although additional comprehensive studies are still required.en_US
dc.description.sponsorshipMustafa Kemal University (Hatay, Turkey) Scientific Research Projects Committee [03M0116]en_US
dc.description.sponsorshipThis study was supported by the Mustafa Kemal University (Hatay, Turkey) Scientific Research Projects Committee (Project No. 03M0116).en_US
dc.identifier.doi10.3906/sag-1401-108
dc.identifier.endpage290en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue2en_US
dc.identifier.pmid26084116en_US
dc.identifier.scopus2-s2.0-84926358686en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage284en_US
dc.identifier.trdizinid170930en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1401-108
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/170930
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22235
dc.identifier.volume45en_US
dc.identifier.wosWOS:000352482000005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLungen_US
dc.subjectEpithelial Cellsen_US
dc.subjectBeraprost Sodiumen_US
dc.subjectLipopolysaccharideen_US
dc.subjectInflammationen_US
dc.subjectOxidative Stressen_US
dc.subjectVascular Endothelial-Cellsen_US
dc.subjectCyclic-Ampen_US
dc.subjectOxidative Stressen_US
dc.subjectStable Analogen_US
dc.subjectInflammationen_US
dc.subjectMacrophagesen_US
dc.subjectSignalen_US
dc.subjectExpressionen_US
dc.subjectReceptoren_US
dc.titleBeraprost sodium, a prostacyclin (PGI) analogue, ameliorates lipopolysaccharide-induced cellular injury in lung alveolar epithelial cellsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu